Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024

Commentary
Video

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington gave a background on ASGCT, its founding, and how far the field has come since.

“There are so many clinical gene therapies, so many approved gene therapies, and cell therapies, and RNA therapies, that it's come to dominate the meeting a little bit. So, one of the things we decided to do is take a tiny step backwards, and not forget about the basic research that got us to where we are today.”

The American Society of Gene and Cell Therapy (ASGCT) is set to hold its 27th Annual Meeting on May 7-11, in Baltimore, Maryland. The meeting brings together researchers, clinicians, academic centers, regulatory agencies, and industry involved in gene and cell therapy work to share their work and generate collaborative discussions in the field. ASGCT expects over 8000 attendees, setting up this year’s meeting to be the biggest yet.

CGTLive® spoke with Jeffrey Chamberlain, PhD, Professor, Neurology and Medical Genetics, and Adjunct Professor, Biochemistry, and McCaw Endowed Chair, Muscular Dystrophy, University of Washington, who has served as ASGCT’s president for 2023-2024, to learn more about the upcoming meeting and the progress of gene and cell therapy in recent years. He shared some background on the ASGCT and how it was founded by George Stamatoyannopoulos to encourage gene therapy research in 1996. He talked about how far the field has come since. He also stressed that this year’s meeting will have a focus on returning to basic science and genetics to better understand and be able to develop treatments for genetic diseases, including translational research studies. The meeting also aims to better highlight pivotal basic science and the researchers behind it.

Click here to register for the 2024 Annual ASGCT Meeting.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.